Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 2-Mercaptoethanesulfonic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Mercaptoethanesulfonic Acid SCHEMBL2301571 | 1.00 | KDM4E (1.00) | — | |
| 2-Mercaptoethanesulfonic Acid SCHEMBL26112497 | 0.97 | — | — | |
| 2-Mercaptoethanesulfonic Acid SCHEMBL21333894 | 0.97 | — | — | |
| 2-Mercaptoethanesulfonic Acid SCHEMBL10412576 | 0.93 | KDM4E (0.88) | — | |
| 2-Mercaptoethanesulfonic Acid SCHEMBL3271658 | 0.93 | — | — | |
| 2-Mercaptoethanesulfonic Acid SCHEMBL8048597 | 0.93 | — | — | |
| 2-Mercaptoethanesulfonic Acid SCHEMBL14988940 | 0.93 | — | — | |
| 2-Mercaptoethanesulfonic Acid SCHEMBL6316228 | 0.93 | — | — | |
| 2-Mercaptoethanesulfonic Acid SCHEMBL8048601 | 0.93 | KDM4E (0.88) | — | |
| 2-Mercaptoethanesulfonic Acid SCHEMBL10413265 | 0.93 | KDM4E (0.88) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 35576 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746899-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH TROP-2 TARGETING ADC | Iovance Biotherapeutics, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4743565-A2 | CYTOKINE ENCODING LENTIVIRAL VECTORS AND USES THEREOF FOR MAKING TUMOR INFILTRATING LYMPHOCYTES | Iovance Biotherapeutics, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| US-20260124300-A1 | COMBINATION TREATMENT OF AN ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY AND CHEMOTHERAPY | HOFFMANN LA ROCHE (US) | 2026-05-07 | — | — | US | claimed |
| EP-4317959-B1 | MICROCHIP CAPILLARY ELECTROPHORESIS ASSAYS AND REAGENTS | REGENERON PHARMA (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108476-A1 | 2,4 DNP and Prodrugs Thereof for Treatment of Cancer | MITOCHON PHARMACEUTICALS, INC. (US) | 2026-04-23 | — | — | US | claimed |
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2026-04-23 | — | — | US | claimed |
| EP-4729063-A2 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGbio, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4724583-A1 | DNA-BINDING PROTEIN-A MODULATOR FOR THE TREATMENT OF RENAL ISCHEMIA/REPERFUSION INJURY | Otto-von-Guericke-Universität Magdeburg (DE) | 2026-04-15 | — | — | EP | claimed |
| EP-0546951-A1 | Combination of liposome encapsulated antineoplastic agents, such as doxorubicin with colony stimulating factors | THE LIPOSOME COMPANY, INC. (US) | 1993-06-16 | — | — | EP | claimed |
| EP-0538858-A1 | Improved lyophilized ifosfamide compositions | Bristol-Myers Squibb Company (US) | 1993-04-28 | — | — | EP | claimed |
| CN-1058337-A | The tablet and the medicine grain that contain mistabrom sodium | ASTA PHARMA AG (DE) | 1992-02-05 | — | — | CN | claimed |
| EP-0468245-A1 | Tablet and granulate containing MESNA as active agent | ASTA Medica Aktiengesellschaft (DE) | 1992-01-29 | — | — | EP | claimed |
| EP-0334083-B1 | IFOSFAMIDE-MESNA-LYOPHILIZED COMPOSITION AND PROCESS TO PREPARE IT | ASTA Pharma Aktiengesellschaft (DE) | 1991-07-24 | — | — | EP | claimed |
| US-4959215-A | FREEZE DRYING WITH A HEXITOL, STORAGE STABILITY | ASTA PHARMA AG (DE) | 1990-09-25 | — | — | US | claimed |
| US-4939291-A | Process for the preparation of mercaptoethansulfonic acid and sodium salt thereof | SCHERING SPA (IT) | 1990-07-03 | — | — | US | claimed |
| US-4927762-A | GROWTH OF HYBRIDOMAS IN SERUM-FREE MEDIUM CONTAINING A THIOL COMPOUND | CELL ENTERPRISES, INC. (US) | 1990-05-22 | — | — | US | claimed |
| EP-0334083-A1 | Ifosfamide-mesna-lyophilized composition and process to prepare it | ASTA Pharma Aktiengesellschaft (DE) | 1989-09-27 | — | — | EP | claimed |
| EP-0263556-A2 | A process for the preparation of saline derivatives of mercaptoethansulfonic acid | Schering Spa (IT) | 1988-04-13 | — | — | EP | claimed |